10th International Lung Cancer Congress

The purpose of the 10th International Lung Cancer Congress is to update participants on advances in lung cancer, including biology, pathology, staging, individualized therapy, novel agents, and supportive care. The congress will discuss current trends in surgical, radiotherapeutic, and chemotherapeutic approaches to lung cancer and will provide a perspective on clinical data presented at major international oncology meetings. An ongoing focus will be the individualization of therapy based on clinical, histologic, and molecular characteristics. Areas of controversy in lung cancer therapy, including treatment of early-stage and locally advanced disease, testing for molecular markers, and the optimal combination of targeted and cytotoxic agents will be the subject of panel discussions and debates. The congress will also feature presentations on optimizing the application of established targeted agents as well as presentations introducing emerging targeted agents, including mechanisms of action and clinical/preclinical results. A regular feature of the International Lung Cancer Congress is an update of research efforts from major Cooperative Groups in the United States, Europe, and Asia. The format of the meeting will include didactic lectures from internationally renowned leaders, debates and discussions on controversial topics, extensive panel discussions with case scenarios, multidisciplinary tumor boards, and question-and-answer sessions as well as afternoon translational workshops focusing on strategies currently in development for the treatment of lung cancer.
Target Audience
This educational program is directed toward medical oncologists, radiation oncologists, thoracic surgeons, and pulmonologists as well as investigators, practitioners, and fellows in training with research interests in lung cancer. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity. Nurses, physician assistants, and other individuals interested in the treatment of lung cancer are also invited to attend.
Learning Objectives

At the conclusion of this congress, you should be able to:

* Summarize clinical data on the efficacy of adjuvant/neoadjuvant chemotherapy for patients with early-stage NSCLC
* Compare the predictive power of tumor stage and molecular profiling in early-stage NSCLC
* Review current issues in the surgical treatment of NSCLC
* Evaluate clinical data on radiation therapy in the treatment of early-stage and locally advanced NSCLC
* Describe combined modality approaches for patients with locally advanced lung cancer
* Assess the feasibility of sublobar resections in early-stage NSCLC
* Summarize the impact of revised staging criteria on lung cancer diagnosis
* Discuss the optimal application of antiangiogenic agents in lung cancer
* Assess approaches to managing toxicities from antiangiogenic agents
* Discuss updates on the use of EGFR TKIs, including the impact of molecular and clinical characteristics and overcoming resistance
* Evaluate clinical data on anti-EGFR antibodies in NSCLC treatment regimens
* Assess clinical data on multikinase inhibitors and epigenetic approaches
* Evaluate approaches to optimize lung cancer therapy based on clinical and molecular characteristics
* Discuss pathologic approaches to categorize lung cancers histologically and molecularly
* Evaluate clinical data on agents used to ameliorate bone health in patients with lung cancer
* Discuss novel cytotoxic and other targeted agents in development for patients with lung cancer
* Evaluate approaches to improve outcomes with frontline and salvage therapy regimens in metastatic NSCLC
* Summarize current research activity in lung cancer from national and regional Cooperative Groups